Arbutus Biopharma Corporation Jun 6, 2024 at 4:00 AM UTC OriginalELI5 Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B In the HBV003 trial, 67% of participants had HBsAg
